---
document_datetime: 2023-09-21 19:41:55
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/airexar-spiromax-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: airexar-spiromax-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.8186737
conversion_datetime: 2025-12-24 05:11:19.886864
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Airexar Spiromax

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10531 /201802  | Periodic Safety Update EU Single assessment - fluticasone / salmeterol (for centrally authorised products)         | 06/09/2018                          | n/a                                            |                                  | PRAC Recommendation - maintenance |
| PSUSA/10531 /201708  | Periodic Safety Update EU Single assessment - fluticasone / salmeterol (for centrally authorised products) product | 08/03/2018                          | n/a                                            |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

edicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0007             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/02/2018   | n/a    |                                          |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|------------------------------------------|
| IB/0006             | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/01/2018   | n/a    |                                          |
| PSUSA/10531 /201702 | Periodic Safety Update EU Single assessment - fluticasone / salmeterol (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/09/2017   | n/a no | PRAC Recommendation - maintenance longer |
| IA/0004/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.III.2.b - Change to comply with Ph. Eur. or with a product | 22/09/2017   | n/a    |                                          |

edicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                           |                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| IAIN/0003 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 08/06/2017 19/02/2018 SmPC and PL                   |
| IAIN/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                             | 09/03/2017 19/02/2018 SmPC, Labelling and PL longer |

edicinal product no longer authorised